Atea Pharmaceuticals Yönetim

Yönetim kriter kontrolleri 2/4

Atea Pharmaceuticals CEO'su Jean-Pierre Sommadossi, Jul2012 tarihinde atandı, in görev süresi 12.33 yıldır. in toplam yıllık tazminatı $ 5.93M olup, şirket hissesi ve opsiyonları dahil olmak üzere 11.5% maaş ve 88.5% ikramiyelerden oluşmaktadır. şirketin hisselerinin 7.09% ine doğrudan sahiptir ve bu hisseler $ 19.68M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 4.3 yıl ve 5.2 yıldır.

Anahtar bilgiler

Jean-Pierre Sommadossi

İcra Kurulu Başkanı

US$5.9m

Toplam tazminat

CEO maaş yüzdesi	11.5%
CEO görev süresi	12.3yrs
CEO sahipliği	7.1%
Yönetim ortalama görev süresi	4.3yrs
Yönetim Kurulu ortalama görev süresi	5.2yrs

Son yönetim güncellemeleri

Recent updates

Analysts Just Shaved Their Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Forecasts Dramatically

Jan 05

Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Analysts Just Slashed Next Year's Estimates

Nov 25

A Look Into The Ownership Structure of Atea Pharmaceuticals (NASDAQ:AVIR)

Oct 24

A Look Into The Ownership Structure of Atea Pharmaceuticals (NASDAQ:AVIR)

Oct 24

Atea Pharmaceuticals' COVID Antiviral Trial Failure Hands Initiative To Merck's Molnupiravir

Oct 20

U.S. to invest more than $3B to boost development of COVID-19 antiviral drugs

Jun 17

Atea Pharmaceuticals, Inc. Beat Analyst Profit Forecasts, And Analysts Have New Estimates

May 15

Market Sentiment Around Loss-Making Atea Pharmaceuticals, Inc. (NASDAQ:AVIR)

May 13

Growth Investors: Industry Analysts Just Upgraded Their Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Revenue Forecasts By 73%

Apr 08

Atea Pharmaceuticals (NASDAQ:AVIR) Is In A Strong Position To Grow Its Business

Mar 06

Need To Know: Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Insiders Have Been Buying Shares

Jan 30

CEO Tazminat Analizi

Jean-Pierre Sommadossi'un ücretlendirmesi Atea Pharmaceuticals'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Jun 30 2024	n/a	n/a	-US$176m
Mar 31 2024	n/a	n/a	-US$164m
Dec 31 2023	US$6m	US$683k	-US$136m
Sep 30 2023	n/a	n/a	-US$131m
Jun 30 2023	n/a	n/a	-US$106m
Mar 31 2023	n/a	n/a	-US$109m
Dec 31 2022	US$6m	US$650k	-US$116m
Sep 30 2022	n/a	n/a	US$36m
Jun 30 2022	n/a	n/a	US$16m
Mar 31 2022	n/a	n/a	US$48m
Dec 31 2021	US$34m	US$650k	US$121m
Sep 30 2021	n/a	n/a	US$25m
Jun 30 2021	n/a	n/a	US$35m
Mar 31 2021	n/a	n/a	US$24m
Dec 31 2020	US$3m	US$437k	-US$11m
Sep 30 2020	n/a	n/a	-US$36m
Jun 30 2020	n/a	n/a	-US$22m
Mar 31 2020	n/a	n/a	-US$16m
Dec 31 2019	US$811k	US$400k	-US$14m

Tazminat ve Piyasa: Jean-Pierre 'nin toplam tazminatı ($USD 5.93M ), US pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 1.48M ).

Tazminat ve Kazançlar: Jean-Pierre şirketinin tazminatı, şirket kârsız olduğu sürece artırıldı.

CEO

Jean-Pierre Sommadossi (68 yo)

12.3yrs

Görev süresi

US$5,925,790

Tazminat

Dr. Jean-Pierre Sommadossi, Ph D., is a Founder of Atea Pharmaceuticals, Inc. and has been its Chairman, Director, Chief Executive Officer and President since July 2012 and had been its Treasurer. Dr. Somm...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Jean-Pierre Sommadossi	Founder	12.3yrs	US$5.93m	7.09% $ 19.7m
Andrea Corcoran	CFO, Executive VP of Legal & Secretary	10.9yrs	US$1.96m	0.79% $ 2.2m
Wayne Foster	Executive VP of Finance & Chief Accounting Officer	2.8yrs	US$1.52m	0.025% $ 68.6k
Janet M. J. Hammond	Chief Development Officer	4.3yrs	US$2.11m	0.042% $ 116.3k
Maria Horga	Chief Medical Officer	4.3yrs	US$1.85m	0.030% $ 84.4k
Jonae Barnes	Senior Vice President of Investor Relations & Corporate Communications	3.8yrs	Veri yok	Veri yok
Ariyapadi Krishnaraj	Vice President of Marketing	2.8yrs	Veri yok	Veri yok
Adel Moussa	Executive Vice President of Chemistry	no data	Veri yok	Veri yok
Xiao-Jian Zhou	Executive Vice President of Early Stage Development	no data	Veri yok	Veri yok
John Vavricka	Chief Commercial Officer	6.1yrs	US$1.52m	0.12% $ 342.2k
Keith Pietropaolo	Executive VP of Clinical Sciences & Project Management	4.8yrs	Veri yok	Veri yok
Jayanthi Wolf	Executive Vice President of Regulatory Affairs	3.8yrs	Veri yok	Veri yok

4.3yrs

Ortalama Görev Süresi

61.5yo

Ortalama Yaş

Deneyimli Yönetim: AVIR 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 4.3 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Jean-Pierre Sommadossi	Founder	12.3yrs	US$5.93m	7.09% $ 19.7m
Barbara Duncan	Independent Director	4.1yrs	US$332.10k	0.039% $ 109.1k
Bruno Lucidi	Independent Director	10.2yrs	US$324.60k	0.098% $ 273.6k
Franklin Berger	Lead Independent Director	5.2yrs	US$357.10k	0.96% $ 2.7m
Bruce Polsky	Independent Director	10yrs	US$324.60k	0.078% $ 215.8k
Polly Murphy	Independent Director	4.3yrs	US$327.10k	0.067% $ 185.7k
Jerome Adams	Independent Director	3.5yrs	US$442.10k	0.039% $ 109.1k

5.2yrs

Ortalama Görev Süresi

64yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: AVIR 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 5.2 yıldır).

Atea Pharmaceuticals Yönetim

Yönetim kriter kontrolleri 2/4

Anahtar bilgiler

Son yönetim güncellemeleri

Founder notifies of intention to sell stock

Independent Director recently sold US$61k worth of stock

Atea Pharmaceuticals, Inc., Annual General Meeting, Jun 21, 2024

Founder notifies of intention to sell stock

Insufficient new directors

Lead Independent Director notifies of intention to sell stock

Recent updates

Founder notifies of intention to sell stock

Atea Pharmaceuticals Provides Update on Global Phase 3 Rise-3 Trial Evaluating Bemnifosbuvir for Treatment of COVID-19

Independent Director recently sold US$61k worth of stock

Price target increased by 18% to US$5.50

Atea Pharmaceuticals Presents Positive Initial Phase 2 Data for Bemnifosbuvir and Ruzasvir Combination for Treatment of Hepatitis C Virus at EASL Congress 2024

Atea Pharmaceuticals Presents New Data Showcasing Potential Best-in-Class Combination Profile of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus at EASL Congress 2024

Atea Pharmaceuticals, Inc., Annual General Meeting, Jun 21, 2024

Atea Pharmaceuticals, Inc. Completes Patient Enrollment in Global Phase 3 Sunrise-3 Trial Evaluating Oral Antiviral Bemnifosbuvir for COVID-19 in High-Risk Patients

Founder notifies of intention to sell stock

Atea Pharmaceuticals, Inc. Announces Positive Initial Data from Phase 2 Study for Hepatitis C Virus (HCV) and Significant Enrollment for Phase 3 SUNRISE-3 Trial for COVID-19

Price target decreased by 15% to US$5.33

Atea Pharmaceuticals, Inc. to Present Bemnifosbuvir and Ruzasvir Data for the Treatment of Hepatitis C Virus at AASLD the Liver Meeting 2023

Atea Pharmaceuticals, Inc. to Report Q3, 2023 Results on Nov 08, 2023

Insufficient new directors

Atea Pharmaceuticals, Inc.(NasdaqGS:AVIR) dropped from Russell 2000 Defensive Index

Atea Pharmaceuticals, Inc. Announces First Patient Dosed in Phase 2 Study for Treatment of Hepatitis C with Bemnifosbuvir and Ruzasvir Combination

Concentra Biosciences, LLC cancelled the acquisition of 96.37% stake in Atea Pharmaceuticals, Inc. (NasdaqGS:AVIR).

Concentra Biosciences, LLC submitted a non-binding proposal to acquire 96.37% stake in Atea Pharmaceuticals, Inc. (NasdaqGS:AVIR) for approximately $480 million.

Investor sentiment deteriorates as stock falls 16%

Price target decreased to US$9.00

Atea Pharmaceuticals, Inc. Provides an Update on the Clinical Development Programs for 2023

Atea Pharmaceuticals, Inc. Announces First Patient Dosed in SUNRISE-3 Phase 3 Registrational Trial of Bemnifosbuvir, an Investigational Oral Antiviral for the Treatment of COVID-19

Lead Independent Director notifies of intention to sell stock

Lead Independent Director recently sold US$215k worth of stock

Third quarter 2022 earnings released: US$0.097 loss per share (vs US$0.34 loss in 3Q 2021)

Atea Pharmaceuticals, Inc. Announces U.S. FDA Fast Track Designation Granted to AT-752 for Treatment of Dengue

Atea wins FDA Fast Track status for dengue treatment

Investor sentiment deteriorated over the past week

Atea Pharmaceuticals, Inc. to Advance Global Phase 3 Registrational Study of Bemnifosbuvir in High-Risk Non-Hospitalized Patients with COVID-19

Consensus forecasts updated

First half 2022 earnings released

Atea Pharmaceuticals Q2 2022 Earnings Preview

Atea Pharmaceuticals, Inc.(NasdaqGS:AVIR) dropped from Russell 2000 Growth Index

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Atea Pharmaceuticals, Inc.'s (NASDAQ:AVIR) Shares Not Telling The Full Story

Atea Pharmaceuticals, Inc., Annual General Meeting, Jun 17, 2022

Price target decreased to US$10.50

Investor sentiment improved over the past week

Full year 2021 earnings: EPS and revenues exceed analyst expectations

Price target decreased to US$11.67

Atea Pharmaceuticals, Inc. Announces Executive Changes

Investor sentiment deteriorated over the past week

Price target decreased to US$15.50

Consensus EPS estimates increase by 131%

Analysts Just Shaved Their Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Forecasts Dramatically

Independent Director recently bought US$103k worth of stock

Consensus forecasts updated

Atea Pharmaceuticals Introduces New Strategic Clinical Development Program for AT-527 in Covid-19

Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Analysts Just Slashed Next Year's Estimates

Investor sentiment deteriorated over the past week

Price target decreased to US$16.25

A Look Into The Ownership Structure of Atea Pharmaceuticals (NASDAQ:AVIR)

A Look Into The Ownership Structure of Atea Pharmaceuticals (NASDAQ:AVIR)

Atea Pharmaceuticals' COVID Antiviral Trial Failure Hands Initiative To Merck's Molnupiravir

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Atea Pharmaceuticals Announces Publication of Data Highlighting AT-752’s Potent In Vitro and In Vivo Activity Against Dengue and Other Flaviviruses

Consensus EPS estimates increase to US$0.62

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Atea Pharmaceuticals, Inc. Announces Positive Interim Results from the Global Phase 2 Study Evaluating AT-527

Independent Director Andrew A. Hack has left the company

Independent Director Andrew A. Hack has left the company

Atea Pharmaceuticals Announces Achievement of AT-527 Development Milestone Under License Agreement with Roche

U.S. to invest more than $3B to boost development of COVID-19 antiviral drugs

Investor sentiment improved over the past week

Consensus revenue estimates increase to US$1.70b

Investor sentiment improved over the past week